Computational Oncology


Computational Oncology Overview


Our groups interest lies in understanding the basis of biological heterogeneity using computational approaches applied to ‘omics data in a disease context. We employ artificial intelligence (AI) and data science (DS) methods, not only to address the underlying causes of this heterogeneity, but also the interactions between different molecular ‘omics layers. We have a strong specialisation in the application area of oncology, but are also very interested in immunology and neurodegenerative diseases.

We believe that by better understanding global and local patterns in biological data, we can better differentiate the mechanistics behind biological and molecular processes from technical noise. As such, we rely on establishing close ties with experimental collaborators who are able to provide us with large scale and high dimensional datasets profiled using state of the art and exotic profiling techniques. We aim to take advantage of recent technological advances that are able to resolve single cell, spatial, temporal and genetic heterogeneity.


Cancer multiomics and precision oncology

The group has a strong core expertise in analysis and interpretation of cancer multiomics data, with exposure to a wide number of omics layers and tumour entities. We are in particular very interested in understanding the heterogeneous patient response to drugs and are interested in accurate classification of tumour entities, patient specific molecular drivers, tumour microenvironment and TILs, tumour evolution and heterogeneity, and germline predisposing factors.

Apoptosis signalling model in colorectal cancer. Together with Prof Heike Algayer we investigated molecular drivers of colorectal cancer using whole genome sequencing. We show that my investigating patterns of gene mutations (shown in the oncoprint, left), we can reconstruct a model of apoptosis signalling (cartoon model, right). Adapted from Ishaque N et al, Nature Commun 2018.

Immunology and allergies

Regulation of innate and adaptive immunity is the primary factor distinguishing healthy and diseased states. Attenuation leaves one susceptible to infections and over activity can lead to autoimmune responses. We have a strong history of collaborating with the group of Irina Lehmann who heads the Molecular Epidemiology department at BIH, and Tobias Boettler and Maike Hoffmann heading the Liver Immunology Lab at Freiburg University Clinic.
Emergence of a Tfh signature on HCV-specific CD4+ T cells after antigen removal. In a collaborative project with Dr Tobias Boettler we investigated expression changes in CD4+ T-cells that were able to recognise HCV, which shifted from a Th1 like phenotype to a Tfh like phenotype. Top row shows the tSNE embedding of HCV-specific T-cells based on FACS marker data, second row shows embedding of various T-cell lineages. Adapted from Smits M et al, JCI 2019.

Spatially resolved transcriptomics

Advances in single cell sequencing has led to better understanding of heterogeneous cell types and cell states. Even more recent advances in in situ transcriptomics allows one to resolve not only cell type and state, but also spatial location. With this information we can, for example, identify the location of different tumour infiltration immune cells in relation to the tumour mass. In the framework of the HCA and with help from the spaceTX consortium, we have recently published a tool called SSAM - the first computational framework for segmentation free cell-type and tissue domain analysis of in situ transcriptomics data.
Reconstruction of the mouse somatosensory cortex (SSp) cell types and tissue structure using SSAM. We applied our SSAM tool to spatially resolved transcriptomics data generated by osmFISH (Codeluppi S et al, 2019). The reconstruction of the cell-type map reveals the cell-type organisation in the tissue (left), and the tissue domain map of cell-type composition motifs identifies cortical layers with the mouse SSp (right). Adapted from Park J et al, bioRxiv 2019.

Community engagement

We are active participants and contributors to various ELIXIR networks, and heavily involved the German ELIXIR node, de.NBI. Committed to the spirit of academic collaboration and transparency, we organise numerous conferences and workshops.
Naveed obtained a M.Sc. in Bioinformatics and Systems Biology at Imperial College London and undertook his Ph.D. under Jonathan Jones at Sainsbury Laboratory in Norwich, focusing on NGS applications determining host-pathogen interactions. He joined Roland Eils’s lab at DKFZ in Heidelberg in 2013. In 2018, he moved with Roland Eils to Berlin where he leads the Computational Oncology research group.

Naveed Ishaque, Ph.D.

Group leader Computational Oncology

BIH@Charité - Center of Digital Health
Luisenstr. 65
10117 Berlin

Research Group

Johanna Denkena
Senior Bioinformatician
Runbing Han
PhD Student
Yiheng Jiang
PhD Student
Dr. Sebastian Mackowiak
Senior Bioinformatician
Alexander Malt
PhD Student
Niklas Müller-Bötticher
PhD Student
Sebastian Tiesmeyer
PhD Student
Shashwat Sahay
PhD Student


  • Park, J.*, Choi, W.*, Tiesmeyer, S., Long, B., Borm, L. E., Garren, E., Nguyen, T. N., Tasic, B., Codeluppi, S., Graf, T., Schlesner, M., Stegle, O., Eils, R., & Ishaque, N. § (2021). Cell segmentation-free inference of cell types from in situ transcriptomics data. Nature communications12(1), 3545.
  • Hensel, N.*, Gu, Z.*, Sagar*, Wieland, D., Jechow, K., Kemming, J., Llewellyn-Lacey, S., Gostick, E., Sogukpinar, O., Emmerich, F., Price, D. A., Bengsch, B., Boettler, T., Neumann-Haefelin, C., Eils, R., Conrad, C., Bartenschlager, R., Grün, D., Ishaque, N. , Thimme, R. §, Hofmann, M§. (2021). Memory-like HCV-specific CD8+T cells retain a molecular scar after cure of chronic HCV infection. Nature immunology22(2), 229–239.
  • Gu, Z., Eils, R., Schlesner, M., & Ishaque, N. (2018). EnrichedHeatmap: an R/Bioconductor package for comprehensive visualization of genomic signal associations. BMC genomics19(1), 234.
  • Ishaque, N.*, Abba, M.L.*, Hauser, C., Patil, N., Paramasivam, N., Huebschmann, D., Leupold, J.H., Balasubramanian, G.P., Kleinheinz, K., Toprak, U.H., Hutter, B., Benner, A., Shavinskaya, A., Zhou, C., Gu, Z., Kerssemakers, J., Marx, A., Moniuszko, M., Kozlowski, M., Reszec, J., Niklinski, J., Eils, J., Schlesner, M., Eils, R., Brors, B. & Allgayer, H.§ (2018). Whole genome sequencing puts forward hypotheses on metastasis evolution and therapy in colorectal cancer. Nature Communications, 9(1), 4782.
  • Wegert, J.*, Ishaque, N.*, Vardapour, R., Geörg, C., Gu, Z., Bieg, M., Ziegler, B., Bausenwein, S., Nourkami, N., Ludwig, N., Keller, A., Grimm, C., Kneitz, S., Williams, R.D., Chagtai, T., Pritchard-Jones, K., van Sluis, P., Volckmann, R., Koster, J., Versteeg, R., Acha, T., O'Sullivan, M.J., Bode, P.K., Niggli, F., Tytgat, G.A., van Tinteren, H., van den Heuvel-Eibrink, M.M., Meese, E., Vokuhl, C., Leuschner, I., Graf, N., Eils, R., Pfister, S.M., Kool, M.§ & Gessler, M.§ (2015). Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors. Cancer Cell, 9;27(2):298-311.

*these authors contributed equally

§corresponding author

Latest News

SBHD 2024

Our colleagues at Vanderbilt University organise the 16th INTERNATIONAL CONFERENCE ON SYSTEMS BIOLOGY OF HUMAN DISEASE – SBHD 2024 this year from June 10-12. Don’t miss the opportunity to participate

Top 100 Köpfe der Wissenschaft 2023

Am 11.10.2023 wurde Prof. Roland Eils im Tagesspiegel als einer der 100 wichtigsten Köpfe der Hauptstadt-Wissenschaft gewürdigt. So schreibt der Tagesspiegel: "Um Big Data dreht sich alles in der

Young BIH scientists attend 72nd Lindau Nobel Laureate Meeting

The Lindau Nobel Laureate Meetings are annual conferences where some of the brightest minds in science converge to exchange knowledge, foster collaboration, and inspire the next generation of

Roland Eils wird als Highly Cited Researcher international gelistet.

Roland Eils gehört zu den weltweit am häufigsten zitierten Forschenden des Jahres 2022, wie aus der Liste der „Highly Cited Researchers“ hervorgeht, die das Unternehmen Clarivate heute veröffentlicht